Compare ONFO & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONFO | SILO |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Apparel |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.9M |
| IPO Year | N/A | 2011 |
| Metric | ONFO | SILO |
|---|---|---|
| Price | $0.55 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.7K | ★ 277.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.22 |
| 52 Week High | $1.95 | $1.44 |
| Indicator | ONFO | SILO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.11 |
| Support Level | N/A | $0.33 |
| Resistance Level | N/A | $0.47 |
| Average True Range (ATR) | 0.00 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 83.15 |
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Onfolio LLC.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.